ERBB2 and breast cancer: In HER2-positive breast cancer patients, the changes in 24 of 33 altered plasma metabolomes 2 weeks after completion of doxorubicin treatment were significantly correlated with the changes in altered cardiac parameters (either LVEF, plasma troponin I or plasma NT-proBNP) 2 weeks after completion of doxorubicin treatment, as detailed in Fig. 4.